Clinical Trial: Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07925619) titled 'Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers' on Oct. 29.

Brief Summary: This trial is designed to evaluate the efficacy and safety of L608 compared to placebo in patients with SSc-DU.

Study Start Date: Feb. 01, 2027

Study Type: INTERVENTIONAL

Condition: Systemic Sclerosis

Intervention: DRUG: L608

Participants will receive L608 TID over 28 consecutive days.

DRUG: Placebo

Participants will receive Placebo TID over 28 consecutive days.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Pharmosa Biopharm Inc.

Disclaimer: Curated by HT Syndication....